These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

249 related items for PubMed ID: 25103491

  • 1. Generation of a vancomycin-intermediate Staphylococcus aureus (VISA) strain by two amino acid exchanges in VraS.
    Berscheid A, François P, Strittmatter A, Gottschalk G, Schrenzel J, Sass P, Bierbaum G.
    J Antimicrob Chemother; 2014 Dec; 69(12):3190-8. PubMed ID: 25103491
    [Abstract] [Full Text] [Related]

  • 2. The Role of β-Glycosylated Wall Teichoic Acids in the Reduction of Vancomycin Susceptibility in Vancomycin-Intermediate Staphylococcus aureus.
    Hort M, Bertsche U, Nozinovic S, Dietrich A, Schrötter AS, Mildenberger L, Axtmann K, Berscheid A, Bierbaum G.
    Microbiol Spectr; 2021 Oct 31; 9(2):e0052821. PubMed ID: 34668723
    [Abstract] [Full Text] [Related]

  • 3. Role of stop codons in development and loss of vancomycin non-susceptibility in methicillin-resistant Staphylococcus aureus.
    Doddangoudar VC, O'Donoghue MM, Chong EY, Tsang DN, Boost MV.
    J Antimicrob Chemother; 2012 Sep 31; 67(9):2101-6. PubMed ID: 22643192
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. WalK(S221P), a naturally occurring mutation, confers vancomycin resistance in VISA strain XN108.
    Peng H, Hu Q, Shang W, Yuan J, Zhang X, Liu H, Zheng Y, Hu Z, Yang Y, Tan L, Li S, Hu X, Li M, Rao X.
    J Antimicrob Chemother; 2017 Apr 01; 72(4):1006-1013. PubMed ID: 27999059
    [Abstract] [Full Text] [Related]

  • 7. Selection of heterogeneous vancomycin-intermediate Staphylococcus aureus by imipenem.
    Katayama Y, Murakami-Kuroda H, Cui L, Hiramatsu K.
    Antimicrob Agents Chemother; 2009 Aug 01; 53(8):3190-6. PubMed ID: 19451283
    [Abstract] [Full Text] [Related]

  • 8. walK and clpP mutations confer reduced vancomycin susceptibility in Staphylococcus aureus.
    Shoji M, Cui L, Iizuka R, Komoto A, Neoh HM, Watanabe Y, Hishinuma T, Hiramatsu K.
    Antimicrob Agents Chemother; 2011 Aug 01; 55(8):3870-81. PubMed ID: 21628539
    [Abstract] [Full Text] [Related]

  • 9. Mechanisms of in-vitro-selected daptomycin-non-susceptibility in Staphylococcus aureus.
    Patel D, Husain M, Vidaillac C, Steed ME, Rybak MJ, Seo SM, Kaatz GW.
    Int J Antimicrob Agents; 2011 Nov 01; 38(5):442-6. PubMed ID: 21840181
    [Abstract] [Full Text] [Related]

  • 10. DNA microarray-based identification of genes associated with glycopeptide resistance in Staphylococcus aureus.
    Cui L, Lian JQ, Neoh HM, Reyes E, Hiramatsu K.
    Antimicrob Agents Chemother; 2005 Aug 01; 49(8):3404-13. PubMed ID: 16048954
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia.
    Howden BP, Johnson PD, Ward PB, Stinear TP, Davies JK.
    Antimicrob Agents Chemother; 2006 Sep 01; 50(9):3039-47. PubMed ID: 16940100
    [Abstract] [Full Text] [Related]

  • 14. Transcriptional profiling of the two-component regulatory system VraSR in Staphylococcus aureus with low-level vancomycin resistance.
    Chen H, Xiong Z, Liu K, Li S, Wang R, Wang X, Zhang Y, Wang H.
    Int J Antimicrob Agents; 2016 May 01; 47(5):362-7. PubMed ID: 27084050
    [Abstract] [Full Text] [Related]

  • 15. Serial daptomycin selection generates daptomycin-nonsusceptible Staphylococcus aureus strains with a heterogeneous vancomycin-intermediate phenotype.
    Camargo IL, Neoh HM, Cui L, Hiramatsu K.
    Antimicrob Agents Chemother; 2008 Dec 01; 52(12):4289-99. PubMed ID: 18824611
    [Abstract] [Full Text] [Related]

  • 16. A mutation in the PP2C phosphatase gene in a Staphylococcus aureus USA300 clinical isolate with reduced susceptibility to vancomycin and daptomycin.
    Passalacqua KD, Satola SW, Crispell EK, Read TD.
    Antimicrob Agents Chemother; 2012 Oct 01; 56(10):5212-23. PubMed ID: 22850507
    [Abstract] [Full Text] [Related]

  • 17. Mutation of RNA polymerase beta subunit (rpoB) promotes hVISA-to-VISA phenotypic conversion of strain Mu3.
    Matsuo M, Hishinuma T, Katayama Y, Cui L, Kapi M, Hiramatsu K.
    Antimicrob Agents Chemother; 2011 Sep 01; 55(9):4188-95. PubMed ID: 21746940
    [Abstract] [Full Text] [Related]

  • 18. Insights into the molecular basis of reduced vancomycin susceptibility among three prominent Staphylococcus aureus clonal complexes.
    Malachowa N, Sturdevant DE, Porter AR, Martin G, Martens C, Nair V, Hansen B, Ricklefs S, Jenkins SG, Chen L, Kreiswirth BN, DeLeo FR.
    Microbiol Spectr; 2024 Aug 06; 12(8):e0048624. PubMed ID: 38916317
    [Abstract] [Full Text] [Related]

  • 19. Teicoplanin resistance in Staphylococcus haemolyticus is associated with mutations in histidine kinases VraS and WalK.
    Vimberg V, Cavanagh JP, Benada O, Kofroňová O, Hjerde E, Zieglerová L, Balíková Novotná G.
    Diagn Microbiol Infect Dis; 2018 Mar 06; 90(3):233-240. PubMed ID: 29246777
    [Abstract] [Full Text] [Related]

  • 20. Prevalence of amino acid changes in the yvqF, vraSR, graSR, and tcaRAB genes from vancomycin intermediate resistant Staphylococcus aureus.
    Yoo JI, Kim JW, Kang GS, Kim HS, Yoo JS, Lee YS.
    J Microbiol; 2013 Apr 06; 51(2):160-5. PubMed ID: 23625215
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.